dexamethasone,lenalidomide,carfilzomib
amgen
['mmsm', 'atlas']
myeloma time! atlas trial compares krd maintenance with len maintenance. as dr voorhees asks: at what point to side effects. treatment fatigue and cost outweigh improvements in pfs? (and why is pfs the primary endpoint of a maintenance trial?) #mmsm #asco22 #atlas
haematology registrar | evidence-based medicine | MPH @Harvard | health policy @PORTAL_research | physiology | musician | writer | @_futurethinkers cofounder